Spots Global Cancer Trial Database for venclexta
Every month we try and update this database with for venclexta cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets | NCT05215639 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | NCT02203773 | Acute Myelogeno... Myelogenous Leu... Treatment Naive... | Posaconazole ABT-199 Decitabine Azacitidine | 60 Years - | AbbVie | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada | NCT05424562 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | NCT03342144 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | NCT05587049 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia | NCT04813263 | Acute Myeloid L... | - | AbbVie | ||
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) | NCT04887857 | Leukemia, Myelo... | CC-486 Venetoclax | 18 Years - | Celgene | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | NCT04895436 | Chronic Lymphoc... | Venetoclax Obinutuzumab | 18 Years - | AbbVie | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | NCT03826992 | Leukemia | Vyxeos Venetoclax | 1 Year - 39 Years | Children's Hospital Medical Center, Cincinnati | |
| Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | NCT04912063 | Acute Myeloid L... Myelodysplastic... | Lemzoparlimab Azacitidine Venetoclax | 18 Years - | AbbVie | |
| Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | NCT03826992 | Leukemia | Vyxeos Venetoclax | 1 Year - 39 Years | Children's Hospital Medical Center, Cincinnati | |
| Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China | NCT05144243 | Acute Myeloid L... | Venetoclax Azacitidine | 18 Years - | AbbVie | |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | NCT03236857 | Malignancies Acute Lymphobla... Acute Myeloid L... Non-Hodgkin's L... Neuroblastoma | chemotherapy venetoclax | 0 Years - 25 Years | AbbVie | |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada | NCT05424562 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | NCT04895436 | Chronic Lymphoc... | Venetoclax Obinutuzumab | 18 Years - | AbbVie | |
| Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia | NCT04655261 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | NCT03342144 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | NCT03873493 | Leukemia T-cell Prolymph... Cancer | Venetoclax Ibrutinib | 18 Years - | AbbVie | |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets | NCT05215639 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | NCT04401748 | Myelodysplastic... | Venetoclax Azacitidine Placebo | 18 Years - | AbbVie | |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02966756 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax | 18 Years - | AbbVie | |
| A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy | NCT06058741 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia | NCT04813263 | Acute Myeloid L... | - | AbbVie | ||
| Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia | NCT04655261 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | NCT05587049 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece | NCT05317494 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China | NCT05144243 | Acute Myeloid L... | Venetoclax Azacitidine | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
